Code Quota Antidote Hd 6.1
Dortha Chuang
Early in my software career, I was placed on a project midstream in order to help increase the velocity of the team. The main purpose of the software was to configure custom products on ecommerce sites.
I was tasked with generating dynamic terms and conditions. There was conditional verbiage that depended on the type of product being purchased, as well as which US state the customer was located in due to legal requirements.
The concept of artificial intelligence has been around for quite some time, although the high profile advances have raised concerns in the media as well as Congress. Artificial intelligence has already been very successful in certain areas. The first one that comes to mind is chess.
Chess always starts with 32 pieces on 64 squares, has well documented officially agreed upon rules, and most importantly has a clearly defined objective. In each turn, there are a finite number of possible moves. Playing chess is just following a rules engine. AI systems can calculate the repercussions of every move to select the move most likely outcome to capture an opponent's piece or gain position, and ultimately win.
There has been another front where AI has been very active - self driving cars. Manufacturers have been promising self-driving cars for quite some time. Some have the capacity to self-drive, but there are caveats. In many situations the car requires active supervision; the driver may need to keep their hands on the wheel, the self-driving feature is not autonomous.
Like chess-playing AI programs, self-driving cars largely use rules-based engines to make decisions. Unlike the chess programs, the rules on how to navigate every possible situation are not clearly defined. There are thousands of little judgments drivers make in a given trip avoiding pedestrians, navigating around double-parked cars, and turning in busy intersections. Getting those judgments right means the difference between arriving at the mall safely or arriving at the hospital.
After all these questions, the team came to the same conclusion. We decided it would be best not to go through with it. Believe it or not, I'd say this was actually a successful outcome. It would have been more wasteful to have gone ahead without a clear resolution for all of the potential errors when invalid user data was submitted.
Is the idea behind using AI to create software to just let those same stakeholders talk directly to a computer to create a SMS based survey? Is AI going to ask probing questions about how to handle all the possible issues of collecting survey data via SMS? Is it going to account for all the things that we as human beings might do incorrectly along the way and how to handle those missteps?
In order to produce a functional piece of software from AI, you need to know what you want and be able to clearly and precisely define it. There are times when I'm writing software just for myself where I don't realize some of the difficulties and challenges until I actually start writing code.
Over the past decade, the software industry has transitioned from the waterfall methodology to agile. Waterfall defines exactly what you want before any code is written, while agile allows enough flexibility so you can make adjustments along the way.
So many software projects using waterfall have failed because the stakeholders thought they knew what they wanted and thought they could accurately describe it and document it, only to be very disappointed when the final product was delivered. Agile software development is supposed to be an antidote to this process.
AI might be best suited to rewrite the software we already have but need to rewrite it to use newer hardware or a more modern programming language. There are still a lot of institutions with software written in COBOL, but there are fewer programmers learning how to use it. If you know exactly what you want, maybe you could get AI to produce software faster and cheaper than a team of human programmers. I believe AI could create the software that has already been created faster than human programmers but that's because someone figured out what that software should do along the way.
Etorphine is available legally only for veterinary use and is strictly governed by law. It is often used to immobilize elephants and other large mammals. Diprenorphine (Revivon) is an opioid receptor antagonist that can be administered in proportion to the amount of etorphine used (1.3 times) to reverse its effects. Veterinary-strength etorphine is fatal to humans. For this reason the package as supplied to vets always includes the human antidote along with the etorphine.
The human antidote is generally naloxone, not diprenorphine, and is always prepared before the preparation of etorphine to be immediately administered following accidental human exposure to etorphine. The LD50 in humans is 3 μg which led to the requirement that the medicine include an equal dose of an antidote, diprenorphine or naloxone.
One of its main advantages is its speed of operation, and more importantly, the speed that diprenorphine reverses its effects. The high incidence of side effects, including severe cardiopulmonary depression, has caused etorphine to fall into disfavor in general veterinary practice. However, its high potency, combined with the rapid action of both etorphine and its antagonist, diprenorphine, means that it has found a place for use in the capture of large mammals such as rhinoceroses and elephants, where rapid onset and rapid recovery are both very important. The high potency of etorphine means that sufficient etorphine can be administered to large wild mammals by projectile syringe (dart).
Etorphine is an extremely potent, non-selective full agonist of the μ-, δ-, and κ-opioid receptors.[6][7] It also has relatively weak affinity for the nociceptin receptor.[8] Etorphine has an LD50 of 3 μg in humans.[9]
In Hong Kong, etorphine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can be used legally only by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without prescription can be fined $10,000 (HKD). The penalty for trafficking or manufacturing the substance is a $5,000,000 (HKD) fine and life imprisonment. Possession of the substance for consumption without license from the Department of Health is illegal with a $1,000,000 (HKD) fine and/or 7 years of jail time.[10]
In the US, etorphine is listed as a Schedule I drug with an ACSCN of 9056, although its hydrochloride salt is classified as Schedule II with an ACSCN of 9059.[12] The 2013 annual aggregate manufacturing quota for both was zero so veterinary supplies of the hydrochloride are presumably imported from Germany and/or the UK. [citation needed]
Phenylephrine primarily acts as an alpha-1 adrenergic receptor agonist and exhibits minimal to no beta-adrenergic activity. Consequently, the medication is an optimal choice for raising mean arterial pressure by inducing vasoconstriction in both veins and arteries and enhancing cardiac preload without exerting significant effects on cardiac myocytes. The US Food and Drug Administration (FDA) has approved intravenous phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. Phenylephrine HCL is also an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels. Furthermore, this medication is administered intranasally to treat uncomplicated nasal congestion and is an OTC additive to topical hemorrhoid medications.
This activity provides a comprehensive overview of the indications, mechanism of action, administration methods, adverse event profile, contraindications, monitoring, and toxicity of phenylephrine relevant to the interprofessional healthcare team to effectively guide patient therapy in the treatment of diverse conditions for which phenylephrine is indicated.
Objectives:
- Identify the clinical uses of phenylephrine for the treatment of hypotension caused by vasodilation, such as in septic shock and anesthesia.Assess patient responses to phenylephrine therapy and monitor hemodynamic parameters and adverse events to ensure optimal outcomes and early recognition of complications.Screen patients for contraindications and potential interactions with phenylephrine, particularly in hypersensitivity, bradycardia, severe cardiac dysfunction, and hypovolemia.Collaborate with the interprofessional healthcare team and communicate clearly with pharmacists and nurses to ensure accurate dosing and administration of phenylephrine, thereby improving outcomes and enhancing patient safety.
The US Food and Drug Administration (FDA) has approved intravenous (IV) phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. In addition, phenylephrine HCL serves as an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels. Furthermore, this medication is administered intranasally to treat uncomplicated nasal congestion and is an OTC additive to topical hemorrhoid medications.[1][2]
Phenylephrine is infrequently utilized off-label as an adjunct to neuraxial or peripheral nerve blockade to treat priapism and other conditions, where the intended outcome is localized vasoconstriction and reduced blood flow.
In IV administration, phenylephrine is frequently used as an anesthetic vasopressor for patients exhibiting normal cardiac function and experiencing hypotension due to the vasodilatory effect of anesthetic medications or non-cardiac shock states. The American Urological Association (AUA) endorses using intracavernosal phenylephrine to treat acute ischemic priapism.[3]
7fc3f7cf58